RIPK4 and melanoma: Moreover, Wronski et al. demonstrated that receptor-interacting serine/threonine-protein kinase 4 (RIPK4) knockdown reduces LRP6 and β-catenin-mediated growth, migration and invasion of melanoma cells via Wnt3a activation, resulting in a significant decrease in tumor progression [59].